Squarepoint
ANVS icon

Squarepoint’s Annovis Bio ANVS Stock Holding History

Squarepoint’s Portfolio ANVS Stock Details ANVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-17,200
Closed -$139K – 4996
2024
Q3 		$139K Sell
17,200
-7,800
-31% -$73.1K ﹤0.01% 3794
2024
Q2 		$144K Hold
25,000
– – ﹤0.01% 3732
2024
Q1 		$298K Buy
+25,000
New +$273K ﹤0.01% 3398

Other funds holding ANVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
WFAG
Wescott Financial Advisory Group Philadelphia, Pennsylvania $1.14B AUM 16.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Squarepoint's ANVS Position: Q2 2025 in Review

Squarepoint sold out of Annovis Bio (ANVS) in Q2 2025, closing a stake of 12,574 shares — an estimated $18.9K sold.

Squarepoint first reported a position in ANVS in Q1 2025 and held it in 1 quarter. The position peaked at $18.9K in Q1 2025. 42 funds tracked by Wall St. Rank hold ANVS as of Q2 2025.

  • Squarepoint reported no remaining Annovis Bio position as of Q2 2025 after selling out during the quarter.
  • Squarepoint sold 12,574 Annovis Bio shares in Q2 2025, an estimated $18.9K.
  • Squarepoint first reported a position in Annovis Bio in Q1 2025 and held it in 1 quarter.
  • Squarepoint's Annovis Bio position peaked at $18.9K in Q1 2025.
  • 42 funds tracked by Wall St. Rank held Annovis Bio as of Q2 2025.

Based on Squarepoint's 13F filing for Q2 2025, filed 14 Aug 2025.